| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Carnosic acid (CA) is a rosemary- and sage-derived phenolic diterpene that functions as a redox-active, pro-electrophilic phytochemical. It is best classified as a natural product / nutraceutical lead rather than an approved anticancer drug. Standard abbreviation: CA. Its most defensible mechanistic identity is bifunctional redox modulation: oxidation-enabled KEAP1 sensing with NRF2 activation in stress-responsive normal tissues, but context-dependent ROS elevation and stress-pathway disruption in cancer cells. At present, its oncology relevance is predominantly experimental, with no established regulatory deployment as a cancer therapeutic. Primary mechanisms (ranked):
Bioavailability / PK relevance: CA is lipophilic and orally bioavailable in animal studies, but exposure is formulation-dependent and strongly shaped by oxidation, metabolism, and matrix effects. Brain distribution has been reported after rosemary-extract administration in rodents, supporting CNS relevance more than robust systemic oncology exposure. Translation is constrained by chemical lability and by the likelihood that many direct anticancer in-vitro concentrations are difficult to sustain clinically without optimized delivery. In-vitro vs systemic exposure relevance: Much of the anticancer literature uses roughly 10–50 µM, sometimes higher. That range is mechanistically useful but often above plausible exposure from ordinary dietary rosemary intake, and likely above many supplement-level free-plasma exposures. Accordingly, cancer-cell killing data should be interpreted as lead-compound pharmacology, not as proof that culinary or standard nutraceutical exposure reproduces the same tumor effects in humans. Clinical evidence status: Preclinical. There are cell-line and animal data across multiple tumor types, plus combination studies suggesting chemosensitization in selected models, but no robust human RCT evidence establishing CA as a stand-alone or standard adjunct anticancer therapy. Carnosic acid (CA) natural antioxidant diterpene found in rosemary and sage.-used in the food industry as a flavouring agent and to provide a major source of natural antioxidants Pathways: -Inhibit the PI3K/Akt pathway, which is typically overactivated in many cancers. -inhibits ERK activation, reducing cell proliferation. -JNK and p38 MAPK: Activation of these kinases by carnosic acid may contribute to stress responses leading to cell cycle arrest or apoptosis. -Block the activation of NF-κB, -Induce apoptosis by disturbing mitochondrial membrane potential, leading to the release of cytochrome c and activation of caspases. -Dual role: as an antioxidant under normal conditions and, in the context of cancer cells, it can induce ROS production beyond a critical threshold. -Interfere with STAT3 activation, -AMPK Activation -Inhibition of Angiogenesis and Metastasis -Induction of endoplasmic reticulum (ER) stress -At lower concentrations, carnosic acid might exhibit antioxidant activity, protecting cells by scavenging free radicals. However, cancer cells often have altered redox balances which can make them more vulnerable to further ROS increases. -While carnosic acid has antioxidant properties in some contexts, it is typically observed to have a prooxidant effect in cancer cells under specific conditions, particularly at concentrations that favor ROS accumulation and the subsequent induction of apoptotic cell death -10-100uM, or 10–100 mg/kg for achieving anticancer effects. -Typically available in standardized rosemary extracts. Carnosic Acid (CA) — Pathway / Axis Effects (Cancer vs Normal)
TSF legend: P: 0–30 min (primary/rapid effects; direct redox interactions) · R: 30 min–3 hr (acute signaling + stress responses) · G: >3 hr (gene-regulatory adaptation; phenotype outcomes) AD and Carnosic AcidCarnosic acid (CA) is a rosemary- and sage-derived phenolic diterpene with significant Alzheimer’s disease relevance, chiefly as a pro-electrophilic neuroprotective agent rather than as a direct anti-amyloid drug. It is best classified in AD as a pleiotropic small-molecule neuroprotective natural product that is oxidatively activated under conditions of cellular stress, enabling selective KEAP1/NRF2 pathway engagement. Standard abbreviation: CA. The strongest AD rationale is reduction of oxidative stress, neuroinflammation, amyloidogenic processing, and downstream neuronal injury, with supporting animal and cell data and recent prodrug work, but no established human efficacy standard or approved AD deployment. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral rosemary-extract studies in rodents detected small quantities of CA and trace CA metabolites in brain, supporting BBB-relevant exposure, but absolute brain exposure appears limited and formulation-sensitive. This is one reason newer prodrug strategies such as diAcCA are being explored to improve brain delivery and disease-modifying potential. In-vitro vs systemic exposure relevance: Much of the mechanistic AD literature uses low-micromolar cell exposure, often in pretreatment paradigms. Those concentrations are pharmacologically informative, but they should not be assumed to arise from ordinary dietary rosemary intake. The AD case is therefore strongest as a brain-directed lead-compound / prodrug platform rather than proof that routine dietary exposure is sufficient. Clinical evidence status: Preclinical. There are multiple cell and animal studies supporting neuroprotection, anti-inflammatory effects, reduced amyloid-related pathology, and cognitive benefit, but there is no robust human RCT evidence establishing CA as an approved or standard AD therapy. AD mechanistic interpretation
TSF legend: P: 0–30 min · R: 30 min–3 hr · G: >3 hr |
| Source: HalifaxProj (inhibit) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Type: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer. ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations. However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS. -mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related) "Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways." "During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity." "ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−". "Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules." Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea. Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells." Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers. -It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis. Note: Products that may raise ROS can be found using this database, by: Filtering on the target of ROS, and selecting the Effect Direction of ↑ Targets to raise ROS (to kill cancer cells): • NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS. -Targeting NOX enzymes can increase ROS levels and induce cancer cell death. -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS • Mitochondrial complex I: Inhibiting can increase ROS production • P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes) • Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels • Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels • Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels • SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels • PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels • HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS • Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production. -Inhibiting fatty acid oxidation can increase ROS levels • ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels • Autophagy: process by which cells recycle damaged organelles and proteins. -Inhibiting autophagy can increase ROS levels and induce cancer cell death. • KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes. -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death. • DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels • PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels • SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels • AMPK activation: regulates energy metabolism and can increase ROS levels when activated. • mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels • HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited. • Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels • Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS. -Increasing lipid peroxidation can increase ROS levels • Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation. -Increasing ferroptosis can increase ROS levels • Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability. -Opening the mPTP can increase ROS levels • BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited. • Caspase-independent cell death: a form of cell death that is regulated by ROS. -Increasing caspase-independent cell death can increase ROS levels • DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS • Epigenetic regulation: process by which gene expression is regulated. -Increasing epigenetic regulation can increase ROS levels -PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS) ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx) -HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more -Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research -Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2) Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference -generated from AI and Cancer database ROS rating: +++ strong | ++ moderate | + weak | ± mixed | 0 none NRF2: ↓ suppressed | ↑ activated | ± mixed | 0 none Conditions: [D] dose [Fe] metal [M] metabolic [O₂] oxygen [L] light [F] formulation [T] tumor-type [C] combination
|
| 5873- | CA, | Carnosic acid serves as a dual Nrf2 activator and PTEN/AKT suppressor to inhibit traumatic heterotopic ossification |
| - | vitro+vivo, | Nor, | NA |
| 5871- | CA, | Carnosic Acid Attenuates an Early Increase in ROS Levels during Adipocyte Differentiation by Suppressing Translation of Nox4 and Inducing Translation of Antioxidant Enzymes |
| - | in-vitro, | Nor, | NA |
| - | vitro+vivo, | Stroke, | PC12 |
| 4264- | CA, | Carnosic Acid Mitigates Depression-Like Behavior in Ovariectomized Mice via Activation of Nrf2HO-1 Pathway |
| - | in-vivo, | NA, | NA |
| 4263- | CA, | Neuroprotective Effects of Carnosic Acid: Insight into Its Mechanisms of Action |
| - | Review, | AD, | NA |
| 5023- | UA, | CA, | RosA, | Therapeutic Effect of Rosemary and Its Active Constituent on Nervous System Disorders |
| - | Review, | Park, | NA | - | Review, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:56 Target#:275 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid